|
Synonyms: Example 10 [WO2014071832] | SAF-189 | SAF-189s
Compound class:
Synthetic organic
Comment: Rufutalkib is the INN for an anaplastic lymphoma kinase (ALK) inhibitor, that was included in WHO INN Proposed List 135 (July 2026). There is a structure match for a compound claimed in patent WO2014071832A1 [2]. Online resources suggest that Fochon Pharmaceutical's lead ALK and ROS proto-oncogene 1 (ROS1) kinase inhibitor SAF-189 is also named foritinib, however this is not a bona fide INN. It is likely that rufutalkib is the proposed INN for SAF-189. SAF-189 is intended as an orally bioavailable anti-tumour agent wit potential to overcome crizotinib resistance [1].
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Fochon Pharma.
SAF-189. Accessed on 03/08/2026. Modified on 03/08/2026. fochonpharma.com, https://fochonpharma.com/what-we-do/saf-189s/ |
|
2. Wang W, Geng M, Ding J, Zhao X, Ai J, Tian Q, Peng X, Zhang W, Liu H, Tan H et al.. (2014)
Alk kinase inhibitors. Patent number: WO2014071832A1. Assignee: Shanghai Institute of Materia Medica of CAS, Shanghai Fochon Pharmaceutical Co Ltd. Priority date: 05/11/2013. Publication date: 15/05/2014. |